06/10/2026 | Press release | Distributed by Public on 06/10/2026 04:03
| Delaware |
|
56-2020050
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(I.R.S. Employer Identification No.)
|
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☒
|
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☒
|
|
Emerging growth company
|
☐
|
| Item 3. |
Incorporation of Certain Documents by Reference.
|
| 1. |
|
|
2. |
|
|
3. |
The Registrant's Current Reports on Form 8-K filed with the Commission on March 2, 2026 (as amended by the Registrant's current report on Form 8-K/A filed with the Commission on April 17, 2026), March 23, 2026 and May 4, 2026; and
|
|
|
4. |
The description of the Common Stock contained in Exhibit 4.1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 17, 2025, including any amendments or reports filed for the purpose of updating such description.
|
| Item 4. |
Description of Securities.
|
| Item 5. |
Interests of Named Experts and Counsel.
|
| Item 6. |
Indemnification of Directors and Officers.
|
|
|
• |
for any breach of the director's duty of loyalty to the Registrant or the Registrant's stockholders;
|
|
|
• |
for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
|
|
|
• |
under Section 174 of the Delaware General Corporation Law; or
|
|
|
• |
for any transaction from which the director derived an improper personal benefit.
|
| Item 7. |
Exemption from Registration Claimed.
|
| Item 8. |
Exhibits.
|
|
Exhibit No.
|
Exhibit Description
|
|
4.1
|
|
|
4.2
|
|
|
4.3
|
|
|
4.4
|
|
|
4.5
|
|
|
4.6
|
|
|
4.7
|
|
|
4.8*
|
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock
|
|
4.9
|
|
|
5.1*
|
Opinion of Gibson, Dunn & Crutcher LLP.
|
|
23.1*
|
Consent of Grant Thornton Zhitong Certified Public Accountants LLP.
|
|
23.2*
|
Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).
|
|
24.1*
|
Power of Attorney (included on the signature page hereto).
|
|
99.1
|
|
|
107.1*
|
Filing Fee Table.
|
| Item 9. |
Undertakings.
|
| (a) |
The undersigned Registrant hereby undertakes:
|
|
|
(1) |
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
|
|
(i)
|
To include any prospectus required by Section 10(a)(3) of the Securities Act;
|
|
|
(ii) |
To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" in the effective Registration Statement; and
|
|
|
(iii) |
To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
|
|
|
(2) |
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
|
|
(3) |
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
|
| (b) |
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
| (c) |
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
|
|
|
Gyre Therapeutics, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Ying Luo, Ph.D.
|
|
|
Name:
|
Ying Luo, Ph.D.
|
|
|
Title:
|
President and Chief Executive Officer
|
|
Signature
|
|
|
Title
|
|
|
|
|
|
| /s/ Ying Luo, Ph.D. |
|
|
President, Chief Executive Officer and Director
|
|
Ying Luo, Ph.D.
|
|
(Principal Executive Officer)
|
|
|
|
|
||
| /s/ Thomas Eastling |
|
|
Chief Financial Officer
|
|
Thomas Eastling
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
||
|
|
|
|
Executive Chairman
|
|
Ping Zhang
|
|
||
|
|
|
||
|
/s/ Gordon G. Carmichael, Ph.D.
|
|
|
Director
|
|
Gordon G. Carmichael, Ph.D.
|
|
||
|
|
|
|
|
|
/s/ David M. Epstein, Ph.D.
|
|
|
Director
|
|
David M. Epstein, Ph.D.
|
|
||
|
|
|
||
|
/s/ Rodney L. Nussbaum
|
|
|
Director
|
|
Rodney L. Nussbaum
|
|
||
|
|
|
||
|
/s/ Renate Parry, Ph.D.
|
|
|
Director
|
|
Renate Parry, Ph.D.
|
|
||
|
|
|
||
|
/s/ Dan Weng, M.D.
|
|
|
Director
|
|
Dan Weng, M.D.
|
|
||